Exploratory biomarker analysis in VERONICA, a phase 2 study of venetoclax plus fulvestrant versus fulvestrant in patients with estrogen receptor (ER)-positive HER2-negative metastatic breast cancer (mBC)

被引：0
|
作者：
Lindeman, Geoffrey J.
Fernando, Tharu M.
Bowen, Rebecca
Chang, Ching-Wei
Desai, Rupal
Gupta, Kushagra
Flechais, Aulde
Wilson, Timothy R.
Bardia, Aditya
机构：
来源：
CANCER RESEARCH | 2022年 / 82卷 / 04期
关键词：
D O I：
10.1158/1538-7445.SABCS21-P5-13-06
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P5-13-06
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Serum thymidine kinase activity in patients with hormone receptor-positive and HER2-negative metastatic breast cancer treated with palbociclib and fulvestrant
    Malorni, Luca
    Tyekucheva, Svitlana'
    Hilbers, Florentine S.
    Ignatiadis, Michail
    Neven, Patrick
    Colleoni, Marco
    Henry, Stephanie
    Ballestrero, Alberto
    Bonetti, Andrea
    Jerusalem, Guy
    Papadimitriou, Konstantinos
    Bernardo, Antonio
    Seles, Elena
    Duhoux, Francois P.
    MacPherson, Iain R.
    Thomson, Alastair
    Davies, David Mark
    Bergqvist, Mattias
    Migliaccio, Ilenia
    Gebhart, Geraldine
    Zoppoli, Gabriele
    Bliss, Judith M.
    Benelli, Matteo
    McCartney, Amelia
    Kammler, Roswitha
    De Swert, Heidi
    Ruepp, Barbara
    Fumagalli, Debora
    Maibach, Rudolf
    Cameron, David
    Loi, Sherene
    Piccart, Martine
    Regan, Meredith M.
    EUROPEAN JOURNAL OF CANCER, 2022, 164 : 39 - 51
  • [22] Final Overall Survival Analysis of Monarch 2: A Phase 3 trial of Abemaciclib Plus Fulvestrant in Patients with Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
    Llombart-Cussac, Antonio
    Sledge, George
    Toi, Masakazu
    Neven, Patrick
    Sohn, Joo Hyuk
    Inoue, Kenichi
    Pivot, Xavier
    Okera, Meena
    Masuda, Norikazu
    Kaufman, Peter A.
    Koh, Han
    Grischke, Eva-Maria
    Conte, PierFranco
    Andre, Valerie
    Bian, Yuanyuan
    Shahir, Ashwin
    van Hal, Gertjan
    CANCER RESEARCH, 2023, 83 (05)
  • [23] Cost-Effectiveness Analysis of Abemaciclib plus Fulvestrant versus Placebo plus Fulvestrant in Patients with Hormone Receptor-Positive, ERBB2-Negative Breast Cancer
    Xie, Qian
    Zheng, Hanrui
    Li, Qiu
    BREAST CARE, 2022, 17 (03) : 237 - 242
  • [24] PYTHIA: A phase II study of palbociclib plus fulvestrant for pretreated patients with ER+/HER2-metastatic breast cancer
    Zardavas, D.
    Regan, M.
    Maibach, R.
    Ruepp, B.
    Hiltbrunner, A.
    Blacher, L.
    Gelber, R.
    Gebhart, G.
    Di Leo, A.
    Hilbers, F.
    Colleoni, M.
    Zoppoli, G.
    Bertelli, G.
    Bliss, J.
    Duhoux, F.
    Piccart, M.
    Malorni, L.
    ANNALS OF ONCOLOGY, 2017, 28
  • [25] A Phase II Trial of Onapristone and Fulvestrant for Patients With ER + and HER2-Metastatic Breast Cancer
    Kamaraju, Sailaja
    Fowler, Amy M.
    Tarima, Sergey
    Chaudhary, Lubna N.
    Burkard, Mark E.
    Giever, Thomas
    Cheng, Yee C.
    Parkes, Amanda
    Lange, Carol A.
    Pipp-Dahm, Michele
    Hegeman, Robert
    Siddiqui, Nauman
    Stella, Amy
    Rajguru, Saurabh
    Twaroski, Kyleigh
    Zurbriggen, Luke
    Jorns, Julie M.
    Rui, Hallgeir
    Keigley, Quinton J.
    Perlman, Scott B.
    Salem, Kelley
    Bradshaw, Tyler J.
    Sahmoud, Tarek
    Wisinski, Kari
    CLINICAL BREAST CANCER, 2025, 25 (03) : 251 - 260
  • [26] Exploratory biomarker analysis of Young-PEARL [palbociclib plus exemestane with GnRH agonist versus capecitabine in premenopausal women with HR (hormone receptor)-positive, HER2-negative metastatic breast cancer (MBC)] study
    Park, Kyunghee
    Kim, Gun Min
    Jung, Kyung Hae
    Kang, Seok Yun
    Park, In Hae
    Kim, Jee Hyun
    Ahn, Hee Kyung
    Park, Woong-Yang
    Im, Seock-Ah
    Park, Yeon Hee
    CANCER RESEARCH, 2021, 81 (04)
  • [27] Treatment of HER2-positive (HER2+) hormone-receptor positive (HR plus ) metastatic breast cancer (mBC) with the novel combination of zanidatamab, palbociclib, and fulvestrant
    Escriva-De-Romani, Santiago
    Alba, Emilio
    Rodriguez-Lescure, Alvaro
    Hurvitz, Sara
    Cejalvo, Juan Miguel
    Gion, Maria
    Ferrario, Cristiano
    Borrego, Manuel Ruiz
    Pezo, Rossanna C.
    Hamilton, Erika
    Webster, Marc
    Pluard, Timothy
    Beeram, Muralidhar
    Rodriguez, Begona Jimenez
    Linden, Hannah
    Saura, Cristina
    Omidpanah, Adam
    Harvey, Phoebe
    Savard, Marie-France
    CANCER RESEARCH, 2023, 83 (05)
  • [28] Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial
    Baselga, Jose
    Im, Seock-Ah
    Iwata, Hiroji
    Cortes, Javier
    De laurentiis, Michele
    Jiang, Zefei
    Arteaga, Carlos L.
    Jonat, Walter
    Clemons, Mark
    Ito, Yoshinori
    Awada, Ahmad
    Chia, Stephen
    Jagiello-Gruszfeld, Agnieszka
    Pistilli, Barbara
    Tseng, Ling-Ming
    Hurvitz, Sara
    Masuda, Norikazu
    Takahashi, Masato
    Vuylsteke, Peter
    Hachemi, Soulef
    Dharan, Bharani
    Di Tomaso, Emmanuelle
    Urban, Patrick
    Massacesi, Cristian
    Campone, Mario
    LANCET ONCOLOGY, 2017, 18 (07): : 904 - 916
  • [29] Real-world efficacy and safety of palbociclib combined with fulvestrant in japanese patients with ER-positive HER2-negative advanced or metastatic breast cancer
    Seki, Hirohito
    Sakurai, Takashi
    Maeda, Yuka
    Oki, Naohiko
    Aoyama, Mina
    Yamaguchi, Ryou
    Shimizu, Ken
    Higeta, Kaori
    CANCER RESEARCH, 2020, 80 (04)
  • [30] Phase II Study of Taselisib (GDC-0032) in Combination with Fulvestrant in Patients with HER2-Negative, Hormone Receptor-Positive Advanced Breast Cancer
    Dickler, Maura N.
    Saura, Cristina
    Richards, Donald A.
    Krop, Ian E.
    Cervantes, Andres
    Bedard, Philippe L.
    Patel, Manish R.
    Pusztai, Lajos
    Oliveira, Mafalda
    Cardenas, Alison K.
    Cui, Na
    Wilson, Timothy R.
    Stout, Thomas J.
    Wei, Michael C.
    Hsu, Jerry Y.
    Baselga, Jose
    CLINICAL CANCER RESEARCH, 2018, 24 (18) : 4380 - 4387
12345